Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

In the most recent trading session, Gilead Sciences (GILD) closed at $91.09, indicating a +0.44% shift from the previous trading day.

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, with a market cap of $115.3 billion, is a global ...

Buying $100 In GILD: If an investor had bought $100 of GILD stock 20 years ago, it would be worth $1,075.53 today based on a ...

Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.

Gilead Sciences (GILD) concluded the recent trading session at $91.86, signifying a -0.57% move from its prior day's close.

Therefore, the Zacks rating upgrade for Gilead basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price. The change in ...

GILEAD SCIENCES, INC. (GILD) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock ...

Gilead Sciences, Inc. (GILD) stock saw a decline, ending the day at $91.86 which represents a decrease of $-0.52 or -0.56% from the prior close of $92.38. The stock opened at $91.66 and touched a low ...

Oppenheimer previewed the upcoming year for the firm’s Biotechnology coverage and said the firm’s top ideas for 2025 are Capricor (CAPR), ...

For years, Gilead Sciences was dead money for shareholders. Shares of the drugmaker, with a market capitalization of just ...